Läkemedel
This page is also available in
Pages
OpinionAntagna on 12/07/2012
Dokumentreferens:
INT/642-EESC-2012-1573
Plenarsession:
482 -
Jul 11, 2012 Jul 12, 2012
EESK:s yttrande: Prices of medicinal products for human use
OpinionAntagna on 28/03/2012
Dokumentreferens:
INT/639-EESC-2012-812
Plenarsession:
479 -
Mar 28, 2012 Mar 29, 2012
EESK:s yttrande: Pharmacovigilance Regulation
OpinionAntagna on 28/03/2012
Dokumentreferens:
INT/638-EESC-2012-811
Plenarsession:
479 -
Mar 28, 2012 Mar 29, 2012
EESK:s yttrande: Pharmacovigilance Directive
OpinionAntagna on 28/03/2012
Dokumentreferens:
INT/637-EESC-2012-810
Plenarsession:
479 -
Mar 28, 2012 Mar 29, 2012
EESK:s yttrande: Information to the general public /medicinal products for human use
OpinionAntagna on 28/03/2012
Dokumentreferens:
INT/636-EESC-2012-809
Plenarsession:
479 -
Mar 28, 2012 Mar 29, 2012
EESK:s yttrande: Information to the general public / Medicinal products subject to medical prescription
OpinionAntagna on 22/02/2012
Dokumentreferens:
INT/602-EESC-2012-469
Plenarsession:
478 -
Feb 22, 2012 Feb 23, 2012
EESK:s yttrande: Information to the general public on medicinal products – Directive
OpinionAntagna on 22/02/2012
Dokumentreferens:
INT/601-EESC-2012-468
Plenarsession:
478 -
Feb 22, 2012 Feb 23, 2012
EESK:s yttrande: Information to the general public on medicinal products - Regulation
OpinionAntagna on 30/09/2009
Dokumentreferens:
INT/478-EESC-2009-1456
Plenarsession:
456 -
Sep 30, 2009 Oct 01, 2009
EESK:s yttrande: Des médicaments sûrs et innovants
OpinionAntagna on 15/07/2009
Dokumentreferens:
TEN/378-EESC-2009-1197
Rapporteur:
Mr Lucien Bouis (Diversity Europe - GR III / France)
Plenarsession:
455 -
Jul 15, 2009 Jul 16, 2009
OpinionAntagna on 15/07/2009
Dokumentreferens:
INT/472-EESC-2009-1191
Plenarsession:
455 -
Jul 15, 2009 Jul 16, 2009
EESK:s yttrande: Prevention of falsified medicinal products
Pages